Every material Form 8-K Propanc Biopharma, Inc. has filed with the SEC since February 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Propanc Biopharma received a Nasdaq notice on October 23, 2026, saying its common stock no longer meets the $1.00 minimum bid price. Because the company had a reverse stock split in the prior year, it is not eligible for a standard compliance period, and Nasdaq says the stock will be delisted on November 2, 2026 unless the company appeals by October 30, 2026. The company intends to appeal, which would stay the delisting, and says it has since cured the deficiency; a delisting would hurt the stock's liquidity and its ability to raise capital.
Nasdaq notice dated October 23, 2026 cites non-compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2)
Stock was below $1.00 based on closing bid prices for the 30 consecutive business days before October 21, 2026
Scheduled delisting from The Nasdaq Capital Market on November 2, 2026, unless an appeal to a hearings panel is requested by October 30, 2026
Company intends to request the appeal, which would keep the stock listed until the Panel decides
Effective July 8, 2026, Annie Van Broekhoven retired and stepped down from Propanc Biopharma's Board of Directors, and the Board appointed Carlo Campiciano to fill the vacancy. The filing describes Mr. Campiciano as a qualified accountant with prior experience as CFO and Company Secretary of MedAdvisor Limited, an ASX-listed company. The change is a board composition update and the filing does not report any financial results.
Annie Van Broekhoven retired and resigned from the Board effective July 8, 2026
Carlo Campiciano appointed to the Board the same day to serve until resignation or removal
Mr. Campiciano was CFO and Company Secretary of MedAdvisor Limited, an ASX-listed company
Director Agreement dated July 8, 2026 with Mr. Campiciano filed as Exhibit 10.1
Dr. Julian Kenyon retired from the Board of Directors of Propanc Biopharma, Inc. effective February 20, 2026, to focus on his personal and family life, and will remain a medical advisor to the company. The same day, the Board filled the vacancy by appointing Dr. Ralf Brant, a pharmaceutical and oncology research executive, to serve until his removal or resignation.
Dr. Julian Kenyon retired and stepped down from the Board effective February 20, 2026, and will remain a medical advisor to the company.
Dr. Ralf Brant was appointed to the Board on February 20, 2026, to fill the vacancy.
The filing describes Dr. Brant as having over thirty years of experience in drug discovery and oncology, and as a serving member of scientific advisory boards including Propanc Biopharma.
Exhibit 10.1, a Director Agreement dated February 20, 2026, is filed with the report; the exhibit names the director as Dr. Ralf Brandt.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Propanc Biopharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →